Cervical Dystonia Market Size & Share, End User (Hospital, Clinics); Drug Type; Treatment - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2025-2037

  • Report ID: 7036
  • Published Date: Jan 23, 2025
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2025-2037

Cervical Dystonia Market size was valued at USD 230.3 million in 2024 and is anticipated to surpass USD 548.5 million by 2037, registering a CAGR of 7.5% during the forecast timeline i.e. 2025-2037. In 2025, the industry size of cervical dystonia is evaluated at USD 247.5 million.

The cervical dystonia market is gaining traction owing to advances in new neuroimaging techniques, genetic research, and neurotoxin therapies. For instance, in February 2024, Philips and Synthetic MR formed an alliance to enhance the diagnosis of neurological diseases in medical diagnostics. They strive to do so through advanced quantitative methods of brain imaging. In addition, precision medicine, where treatment is tailored to the genetic individuality of a person, is now making room for even more effective management strategies. For instance, in August 2023, BostonGene and NEC Corporation announced the formation of BostonGene Japan Inc. This Tokyo-based JV will advance precision medicine and significantly enhance patient outcomes. 

Furthermore, botulinum toxin injections, a minimally invasive procedure are experiencing increased demand, thus making symptom management options more accessible. In addition, the emphasis is given to holistic care hence, integrated treatment with physiotherapy and psychiatric supports the patient. Moreover, advanced diagnostic techniques and patient awareness are propelling cervical dystonia treatment globally. For instance, in August 2021, Sense Neuro Diagnostics announced that the U.S. Army Medical Research and Development Command (USAMRDC) Combat Casualty Care Research Program has selected the company to receive USD 2.43 million from the U.S. Department of Defense. This funding is to advance the development of sensing technology to diagnose and monitor traumatic brain injury (TBI) in a field environment.


Get more information on this report: Request Free Sample PDF

Cervical Dystonia Sector: Growth Drivers and Challenges

Growth Drivers

  • Research and development investments: A growth driver for the cervical dystonia market is mainly fueled by investments to meet the need for innovative and better alternative therapeutic options. The availability of efficacious treatment modalities, such as botulinum toxin injections that have a short-term prognosis, requires significant investments in R&D in the area to explore gene-based treatments and other neuromodulation techniques. For instance, in December 2024, Wavegate received USD 26 million in funding for its neuromodulation technology directed towards chronic pain. The acquired funds will advance the development work on the firm's Ellipse Spinal Cord Stimulator Platform meant for chronic pain treatment.
  • Global healthcare access: The biggest growth driver for the cervical dystonia market is fueled by to increasing availability of state-of-the-art treatments within developing markets. Improved access to state-of-the-art, medical care along with infrastructural advancements in general healthcare systems globally has made easier access to diagnostics equipment and appropriate therapies. For instance, in June 2024, the GOI dedicated five new AIIMS facilities and unveiled a total of 202 health infrastructure projects across India. This includes medical colleges, specialty units, and research facilities. This development alone increases the likelihood of timely diagnosis and intervention for cervical dystonia and also fosters wider acceptance of frontier treatments.

 Challenges

  • Psychosocial impact: One of the challenges in the cervical dystonia market is that the symptoms themselves are visible along with chronic pains, which may render the patient into social stigma with mental health implications. Moreover, both physical inconvenience caused by sickness and the psychic shock of disease that could impair the appearance or mobility of an infected patient has more often made these endure anxiety, depression, and below-par quality of life. Such a psychogenic burden complicates treatment and rehabilitation efforts, as attending to just the physical symptoms without respect to the psychological impacts can readily influence the total well-being and recovery of the patient.
  • Variable treatment options: The most difficult characteristic in the cervical dystonia market is variability in response to therapy, partly due to the inherent idiosyncratic nature of the disorder. Indeed, while botulinum toxin injection is highly effective for most, there are a few for whom the treatment may be only partial or fluctuant, necessitating a constant adaptation of their treatment program. This variability in response poses problems in standardized care protocols and may lead to protracted periods of trial and error and delay optimum management that could jeopardize patient outcomes.

Cervical Dystonia Market: Key Insights

Base Year

2024

Forecast Year

2025-2037

CAGR

7.5%

Base Year Market Size (2024)

USD 230.3 million

Forecast Year Market Size (2037)

USD 548.5 million

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Get more information on this report: Request Free Sample PDF

Cervical Dystonia Segmentation

End user (Hospitals, Research Institutes, Long-term Care Facilities)

The hospital segment is likely to capture cervical dystonia market share of over 50.2% by 2037. primarily due to the facilities that can avail full-fledged care and specialized treatments. Advanced diagnostic tools are now available in hospitals, including neuroimaging, treatments such as botulinum toxin injections, physical therapy, and surgery. For instance, in September 2024, Allergan Aesthetics, an AbbVie company announced BOTOX Cosmetics is now approved in China to treat masseter muscle prominence. Hospitals continue to be the main site of care for most patients who require a multidisciplinary approach to treating the neurological and psychosocial aspects of the condition.

Treatment (Oral Therapy, Intravenous, Surgery, Others)

The oral therapy segment is anticipated to dominate the cervical dystonia market by 2037. It is primarily due to the accessibility and consequently effectiveness for symptomatic management of the disease. The oral drugs administered are mostly of the type of anticholinergics and muscle relaxants, given primarily to relax spasms of muscles and soothe pain due to which it is easy to treat the patients. For instance, in October 2024, AbbVie and Aliada Therapeutics announced a definitive agreement under which AbbVie will acquire Aliada for developing therapies using a novel blood-brain barrier (BBB). These therapies are usually used in addition to other treatments. Oral therapy will still hold its market share because of increased demand for non-invasive patient-friendly treatments.

Our in-depth analysis of the global cervical dystonia market includes the following segments:

End user

  • Hospitals
  • Clinics
  • Others

Treatment

  • Oral Therapy
  • Intravenous
  • Surgery
  • Others

Drug Type

  • Torticollis
  • Retrocollis
  • Laterocollis
  • Others

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Cervical Dystonia Industry - Regional Synopsis

North America Market Statistics   

North America cervical dystonia market is estimated to capture revenue share of over 50.3% by 2037, due to the growing unmet health-care needs. Moreover, a steep increase in the need for advanced medical centers, growing global cases of dystonia, and an increase in the incidence rate of other neurological disorders further propels the market growth. In addition, the prevalence of musculoskeletal conditions varies by age and diagnosis, which furthers the need for better and efficient patient outcomes.

The U.S. cervical dystonia market is experiencing significant growth attributable to the consistent research and development programs going across the country. For instance, in June 2024, Mayo Clinic researchers, and collaborators from all over the world, have set up the Pick's Disease International Consortium to explore a specific MAPT gene variant called MAPT H2, which codes for the tau protein and acts as a disease driver. The researchers were studying the link between the gene and disease risk, age at onset, and duration of Pick's disease.

In Canada, the cervical dystonia market is flourishing due to strong government support and initiatives. For instance, in May 2024, DiagnaMed introduced CERVAI, Brain Health AI in Canada. This AI solution estimates an individual's brain age and provides their brain health score. As part of its announcements in mid-January, the Ontario government committed over three years USD 60 million to support the Ontario Brain Institute in its mission to accelerate solutions to improving brain health. A further USD 5 million will go towards launching the Centre for Analytics - an initiative that supports neuroanalytical skills and AI models.

Asia Pacific Market Analysis

The cervical dystonia market in Asia Pacific is gaining traction and is expected to witness lucrative growth during the forecast timeline i.e. 2025-2037. The healthcare sector is expanding dramatically in this region due to the growing demand for better healthcare services, large government investments to upgrade healthcare infrastructure, and the growth of the medical tourism sector. This will propel the market throughout the projection period for the market.

The China market is growing significantly with the rise in infrastructure developments and equipping them with modern amenities & technologies. For instance, in November 2021, a new Center for Brain Imaging was established by NYU Shanghai and East China Normal University, its sister university. The center, located on the North Zhongshan Road Campus of ECNU, will focus on brain imaging initiatives that will help us better understand how children's brains and intelligence develop.

The India cervical dystonia market is expanding remarkably. This growth is attributed to the presence of tech-giants, who are constantly innovating in technologies that helps in early detection and treatment of abnormalities. For instance, in December 2024, The Indian Institute of Technology, Madras was the world's first scientific institution to publish the most detailed 3D high-resolution photographs of the fetal brain. Improvements in the current fetal imaging technologies for early detection and treatment of developmental abnormalities are the principal uses of producing such high-resolution images of the brain.

Research Nester
Get more information on this report: Request Free Sample PDF

Companies Dominating the Cervical Dystonia Landscape

    The cervical dystonia market is revolutionizing due to the presence of strong tech giants and pharmaceuticals who are collaboratively working to innovate and develop the effortless techniques. Such innovations help the market evolve in delivering better patient outcome. For instance, in June 2022, Amneal Pharmaceuticals, Inc. launched LYVISPAH, an oral granules specialty product for the treatment of spasticity associated with multiple sclerosis and other spinal cord conditions.

    Here's the list of some key players:

    • Revance Therapeutics Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • ALLERGAN
    • Solstice Neurosciences LLC
    • Ipsen Biopharmaceuticals Inc.
    • Merz Inc
    • Addex Therapeutics
    • AbbVie Inc.
    • Eli Lilly and Co.
    • Iovance Biotherapeutics, Inc.

In the News

  • In November 2024, Royal Philips and Icometrix partnered to launch an AI-driven, end-to-end solution for acquiring, reading, and reporting the results of MRI brain scans.  This solution optimizes diagnosis and treatment monitoring of neurological conditions including Alzheimer's and multiple sclerosis (MS).
  • In November 2024, Nihon Kohden announced that it had acquired a 71.4% stake in NeuroAdvanced Corp. The acquisition further consolidates Nihon Kohden's leadership role in the field with a fusion of its well-established credentials in EEG systems Thus bolstering its capacity to deal with more intricate neurological disorders.

Author Credits:  Radhika Pawar


  • Report ID: 7036
  • Published Date: Jan 23, 2025
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of the cervical dystonia market was over USD 230.3 million.

The market size for the cervical dystonia market is projected to reach USD 548.5 million by the end of 2037 expanding at a CAGR of 7.5% during the forecast period i.e., between 2025-2037.

The major players in the market are Ipsen Biopharmaceuticals Inc., Merz Inc., Addex Therapeutics, AbbVie Inc., Eli Lilly and Co., and more.

In terms of end users, the hospital segment is anticipated to garner the largest market share of 50.2% by 2037 and display lucrative growth opportunities during 2025-2037.

The market in North America is projected to account for a prominent share of 50.3% by the end of 2037 and provide more business opportunities in the future.
Cervical Dystonia Market Report Scope
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample